Ansell Healthcare Europe NV/SA

Riverside Business Park – Block J Boulevard International 55 1070 Brussels, Belgium

T. + 32 (0)2 528 74 00 F. + 32 (0)2 528 74 01 Email: info.europe@ansell.com www.ansell.com



EU DECLARATION OF CONFORMITY

Manufacturer Name/Address:	Ansell Healthcare Europe NV/SA Riverside Business Park, Block J, Boulevard International 55, 1070 Brussels, Belgium
	3

SRN Number: BE-MF-00000691

Risk Class: Class I

Intended Purpose: Α non-sterile medical device intended as an examination/treatment glove and a protective barrier when worn on the hands of healthcare providers, during patient examination, or for other sanitary purposes. The device is used mainly as a two-way barrier to protect both the patient and wearer against contaminants. This is a single-use device.

T010201 - Latex Examination/Treatment Gloves EMDN Code and Description:

Basic UDI-DI:

5414566 MTS11U11 YF

Product Name(s):

Product Name	Size	Product Code	Market Regions
Micro-Touch® Sensiclean® II	XS	4566	ANZ
Micro-Touch® Sensiclean® II	S	4560	ANZ
Micro-Touch® Sensiclean® II	М	4562	ANZ
Micro-Touch® Sensiclean® II	L	4564	ANZ
Micro-Touch® Sensiclean® II	XL	4568	ANZ
Micro-Touch® Ultra II	XS	816771	EMEA/ANZ
Micro-Touch® Ultra II	S	816763	EMEA/ANZ
Micro-Touch® Ultra II	М	816767	EMEA/ANZ
Micro-Touch® Ultra II	L	816768	EMEA/ANZ
Micro-Touch® Ultra II	XL	816770	EMEA/ANZ

Conformity Assessment Procedure: Annex I & Annex II + Annex III

This EU Declaration of Conformity is issued under the sole responsibility of Ansell Healthcare Europe NV/SA.

Ansell Healthcare Europe NV/SA

Riverside Business Park – Block J Boulevard International 55 1070 Brussels, Belgium T. + 32 (0)2 528 74 00 F. + 32 (0)2 528 74 01 Email: info.europe@ansell.com www.ansell.com



We hereby declare that the medical device(s) specified above meet the provision of the Regulation (EU) MDR 2017/745 for medical devices.

Signed on behalf of Ansell Healthcare Europe NV

Ansell Healthcare Europe NV Riverside Business Park - Block J Bld Internationalelaan 55 B-1070 Brussels BELGIUM

Name:Samantha MarshallPosition:Director Regulatory Affairs Medical EMEA / APACDate of issue:02 March 2023Place of issue:Nuneaton, EnglandVersion No:MED\MTULTIISENCII\002